Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pasireotide dose-finding study in post-bariatric hypoglycaemia
2023-505316-37-00Phase 2Completed
- Sponsor
- Recordati SpA
- Start
- Jun 2024
- Modality
- Small Molecules, Peptides
- Countries
- 6
01
Overview
Phase 2, randomised, double-blind trial of pasireotide LAR in hypoglycaemia (4 arms), sponsored by Recordati SpA. Primary endpoint: Change in peak-to-nadir glucose AUC during MMTT at week 12. Started Jun 2024; status: completed.
02
Drugs
pasireotide LAR
03
Conditions
hypoglycaemia
Beyond the preview
Go deeper on 2023-505316-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505316-37-00.